In a phase 1/2 clinical trial, a mutant KRAS vaccine, designed to induce T-helper responses, seemed to induce immunologic response in a number of patients with resected pancreatic cancer, and it might be associated with improved long-term immune responses and long-term survival [111]. Here, KRAS is linked to familial pancreatic carcinoma.